A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

This study tests a new experimental drug called BH-30236 in people with relapsed or treatment-resistant acute myeloid leukemia (AML) — a fast-growing blood cancer — or higher-risk myelodysplastic syndrome (MDS), a bone marrow disorder that can turn into leukemia. **You may be eligible if...** - You are 18 or older - You have been diagnosed with relapsed/refractory AML or higher-risk MDS with at least 5% abnormal cells in your bone marrow - You have received 1 to 5 prior lines of treatment - You have reasonable overall health (ECOG score of 2 or lower) - Your liver and kidney functions are within acceptable ranges **You may NOT be eligible if...** - You have a specific type of AML called acute promyelocytic leukemia, or CML in blast crisis - You received a bone marrow/stem cell transplant from a donor within the past 3 months - You have an active, uncontrolled infection - You have unresolved serious side effects from prior treatments - You have another active cancer - You have previously been treated with a CLK inhibitor - You have active graft-versus-host disease (GVHD) requiring strong medications Talk to your doctor to see if this trial is right for you.